# New Dyslipidemias clinical trials: 153 posted since Nov 2024

Updated November 9, 2026.

153 clinical studies in dyslipidemias were first posted on ClinicalTrials.gov from November 19, 2024 to November 9, 2026; 49 have an industry sponsor and 88 are recruiting or about to. The newest, NCT07924345, was posted on November 9, 2026: Observational Study to Evaluate Achieving LDL-cholesterol Target Level to Treat With Rovazet Tab. With... (HK inno.N Corporation).

## The full list

New Dyslipidemias clinical trials: 153 rows for $7.65, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 4 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/condition/dyslipidemias

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 153
- Industry sponsored: 49
- Recruiting or not yet: 88
- Latest posted: November 9, 2026

## Newest trials

The newest 100 of 153, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 9, 2026 | NCT07924345 | Observational Study to Evaluate Achieving LDL-cholesterol Target Level to Treat With Rovazet Tab. With Dyslipidemia Patients | HK inno.N Corporation | Observational | Recruiting | Dyslipidemia | 6,713 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07924345) |
| November 5, 2026 | NCT07919158 | Impact of Dyslipidemia on Metabolic Health of Adults With Overweight/Obesity (IDOM): A Study at the San Raffaele Hospital Center for... | Rovere Querini Patrizia | Observational | Active not recruiting | Dyslipidemia, Obesity & Overweight | 900 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919158) |
| November 4, 2026 | NCT07917676 | Multimodal AI-Driven Out-of-Hospital Management for Hypertension and Cardiometabolic Risk | China National Center for Cardiovascular Diseases | Not applicable | Not yet recruiting | Hypertension, Hyperglycemia, Dyslipidemia | 150 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917676) |
| November 4, 2026 | NCT07917364 | Asprosin and miRNA Expression in Young Women With Metabolic Syndrome | University of Applied Sciences in Nowy Targ | Observational | Recruiting | Metabolic Syndrome, Insulin Resistance, Obesity, Abdominal, Dyslipidemias | 110 | Poland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917364) |
| November 4, 2026 | NCT07915687 | Synbiotic as an Adjuvant Therapy for Dyslipidaemia and Gut Health | Universiti Teknologi Mara | Phase 2 | Not yet recruiting | Dyslipidemia | 190 | Malaysia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915687) |
| November 2, 2026 | NCT07909915 | Effectiveness and Tolerability of a Treat-to-Target Versus Fixed-Dose Statin Strategy in Patients With Atherosclerotic Cardiovascular... | Rehman Medical Institute - RMI | Phase 4 | Not yet recruiting | Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia, Stroke (CVA) or TIA, Cardio Vascular Disease | 178 | Pakistan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909915) |
| November 2, 2026 | NCT07908433 | Study of the Safety and Efficacy of Prenofitol Tablets | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Phase 2 | Not yet recruiting | Dyslipidemia | 160 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908433) |
| October 26, 2026 | NCT07894887 | EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C) | Editas Medicine, Inc. | Phase 1/2 | Not yet recruiting | Heterozygous Familial Hypercholesterolemia (HeFH) | 56 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07894887) |
| October 21, 2026 | NCT07884903 | Chinese Overweight/Obesity Cohort: Metabolic & Comorbidity Risks | Shanxi Bethune Hospital | Observational | Not yet recruiting | Obesity & Overweight, Diabetes Mellitus, Type 2, Hypertension, Non-alcoholic Fatty Liver Disease (MASLD)... | 25,974 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07884903) |
| October 19, 2026 | NCT07880717 | Prevalence and Associated Factors of High BMI and Periodontitis in Thai Adults Aged Under 60 Years | Mahidol University | Observational | Recruiting | Diabete Mellitus, Dyslipidaemia, Chronic Kidney Disease, Psychiatric Disorder, Hypertension, Hypothyroidism, Smoking... | 93 | Thailand | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07880717) |
| October 16, 2026 | NCT07879144 | Digital Nudges to Improve Heart Health Actions After Community Screening in Malaysia (NADI-MyHeartRisk) | Cardiovascular Advancement and Research Excellence Institute | Not applicable | Not yet recruiting | Cardiovascular Diseases, Cardiovascular Risk Factor | 6,588 | Malaysia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07879144) |
| October 13, 2026 | NCT07871565 | Time-Restricted Eating With or Without Energy Restriction in Dyslipidemic Women With Owerweight or Obesity | Acibadem University | Not applicable | Completed | Dyslipidemia, Obesity & Overweight | 56 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871565) |
| September 28, 2026 | NCT07845448 | A Cluster-Randomized Controlled Trial | Second Affiliated Hospital of Nanchang University | Not applicable | Not yet recruiting | Hypertension, Stroke, Cardiovascular, Coronary Heart Disease, Ischemic Heart Disease, Dyslipidaemia, Diabete Mellitus... | 14,400 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07845448) |
| September 25, 2026 | NCT07843238 | Evaluation of a New Virtual Care Pathway for Older Adults With Noncommunicable Diseases | National University of Malaysia | Not applicable | Recruiting | Hypertension (HTN), Diabetes, Dyslipidaemia | 160 | Malaysia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843238) |
| September 22, 2026 | NCT07835282 | Germany on Target Registry | Deutsche Gesellschaft für Lipidologie e. V. (DGFL) - Lipid-Liga | Observational | Not yet recruiting | Myocardial Infarction (MI), Dyslipidemias | 10,000 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07835282) |
| September 18, 2026 | NCT07828990 | Cardiovascular Risk Factors and Lipid Profile in Hospitalized Mexican Adults | Hospital General de Chihuahua - Dr. Salvador Zubirán Anchondo | Observational | Completed | Dyslipidemia | 107 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07828990) |
| September 17, 2026 | NCT07824323 | Early Triple Lipid-Lowering Therapy With Bempedoic Acid After Acute Coronary Syndrome | Taipei Medical University Hospital | Phase 4 | Recruiting | Acute Coronary Syndromes, Dyslipidemia | 400 | Taiwan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07824323) |
| September 2, 2026 | NCT07799129 | Phase 2 Dose-Finding Study Evaluating the Efficacy and Safety of EDP167 in Adults With Mixed Dyslipidemia | Eddingpharm (Zhuhai) Co., Ltd. | Phase 2 | Not yet recruiting | Mixed Dyslipidemia | 144 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07799129) |
| August 24, 2026 | NCT07781371 | A Retrospective Real-World Cohort Study | Novo Nordisk A/S | Observational | Active not recruiting | Obesity, Type 2 Diabetes (T2D), Prediabetes, Cardiovascular Disease (CVD), Dyslipidemia, Metabolic... | 100,000 | Denmark | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07781371) |
| August 20, 2026 | NCT07777003 | A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-10582 in Healthy Subjects and Subjects With Mildly... | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Dyslipidemia | 76 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07777003) |
| July 27, 2026 | NCT07729553 | Vitamin D Status and Lipid Profile in Obese Adults With Type 2 Diabetes | Sinai University | Observational | Not yet recruiting | Type 2 Diabetes Mellitus, Obesity, Dyslipidemia, Vitamin D Deficiency | 150 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07729553) |
| July 24, 2026 | NCT07726368 | Study of ECC4703 With Sulfasalazine and Pitavastatin | Eccogene | Phase 1 | Recruiting | Non-alcoholic Fatty Liver Disease (NAFLD), Dyslipidaemia | 40 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07726368) |
| July 20, 2026 | NCT07715461 | Effect of macaúba Oil Combined With Green Exercises | Federal University of Minas Gerais | Not applicable | Not yet recruiting | Stress Mental, Dyslipidemia, Obesity & Overweight | 60 | Brazil | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07715461) |
| July 17, 2026 | NCT07712367 | Atorvastatin Plus Escitalopram for Depression With Dyslipidemia | Hengshui City Seventh People's Hospital | Observational | Completed | Depressive Episode, Dyslipidemia | 60 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07712367) |
| July 17, 2026 | NCT07710261 | Effects of Policosanol and Exercise on Fitness and Lipids in People With Elevated Blood Lipids | Mahidol University | Not applicable | Not yet recruiting | Dyslipidemia, Elevated Blood Lipids, Physical Fitness, Exercise Training, Muscle Function, Handgrip Strength Test | 120 | Thailand | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07710261) |
| July 16, 2026 | NCT07707778 | Tirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIV | National Taiwan University Clinical Trial Center | Phase 4 | Enrolling by invitation | Human Immunodeficiency Virus (HIV), Metabolic Dysfunction Associated Steatotic Liver Disease, Dyslipidaemia, Diabetes... | 60 | Taiwan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07707778) |
| July 14, 2026 | NCT07703371 | Kodo Millet Porridge and Its Effects on Gut Health and Metabolic Syndrome | JSS MEDICAL COLLEGE, JSS ACADEMY OF HIGHER EDUCATION AND RESEARCH | Not applicable | Recruiting | Obesity & Overweight, Metabolic Syndrome, Gut Dysbiosis, Insulin Resistance, Dyslipidemia | 50 | India | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07703371) |
| July 10, 2026 | NCT07696403 | Cardiometabolic Effects of the Recommended Daily Pecan Intake Dose | University of Georgia | Not applicable | Not yet recruiting | Nutrition, Healthy, Dyslipidemia, Overweight and Obesity | 90 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07696403) |
| July 9, 2026 | NCT07692438 | Taiwan Green Propolis for Blood Lipids and Body Fat in Patients With MASLD | Taipei Medical University | Not applicable | Recruiting | Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease NAFLD, Dyslipidemia... | 60 | Taiwan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07692438) |
| July 8, 2026 | NCT07691268 | Study to Evaluate the Safety and the Pharmacokinetics of "UI111" and "UIC202006" Under Fed Conditions | Korea United Pharm. Inc. | Phase 1 | Completed | Dyslipidemia | 44 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07691268) |
| July 6, 2026 | NCT07685639 | Electronic Health Record Augmented LDL-Cholesterol Optimization and Control Via Active Lipid Engagement (EHR-LOCALE): A Quality Improvement... | University of Alberta | Not applicable | Recruiting | ACS (Acute Coronary Syndrome), Hyperlipidemia, Dyslipidemia, Low-Density-Lipoprotein-cholesterol Level | 2,000 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07685639) |
| July 6, 2026 | NCT07682948 | A Randomized, Open-label, Two-arm, Two-period, Multiple-dose, Study to Evaluate Pharmacokinetic Drug-drug Interaction, Safety and... | Korea United Pharm. Inc. | Phase 1 | Recruiting | Hypertension, Dyslipidemia | 36 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07682948) |
| July 2, 2026 | NCT07682285 | Taiwanese Green Propolis for Lipid Profiles, Fatigue, and Quality of Life in Oral Cavity Cancer Survivors | Taipei Medical University | Not applicable | Completed | Head and Neck Squamous Cell Carcinoma, Cancer-related Fatigue, Dyslipidemias | 25 | Taiwan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07682285) |
| July 1, 2026 | NCT07679828 | Polypills Approach for Multiple Cardiovascular Risk Factors | China Medical University, China | Not applicable | Recruiting | Hypertension, Dyslipidemia, Diabetes | 8,252 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07679828) |
| June 25, 2026 | NCT07668791 | The Efficacy of a Food Supplement Consisting of the Combination of an Olive Extract and a Myrtle Extract for the Improvement of Lipid... | Labomar SPA | Not applicable | Completed | Dyslipidaemias | 112 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07668791) |
| June 18, 2026 | NCT07655960 | To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C716 and C716R in Healthy Adults | AJU Pharm Co., Ltd. | Phase 1 | Completed | Hypercholesterolemia, Dyslipidemia | 41 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07655960) |
| June 16, 2026 | NCT07649577 | Generative AI for Medication Counselling and Adherence in Community Pharmacies | University of Petra | Not applicable | Completed | Hypertension, Diabetes Mellitus, Dyslipidemias, Cardiovascular Diseases, Pulmonary Disease, Chronic Obstructive... | 136 | Jordan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07649577) |
| June 12, 2026 | NCT07644910 | Nudging Preventive Screening Via Message Framing and Bundling | University of Chile | Not applicable | Not yet recruiting | Breast Neoplasms, Uterine Cervical Neoplasms, Colorectal Neoplasms, Prostatic Neoplasms, Diabetes Mellitus... | 235,000 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07644910) |
| June 8, 2026 | NCT07634510 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MWX205 | Shanghai Minwei Biotechnology Co., Ltd | Phase 1 | Not yet recruiting | Dyslipidemias | 37 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07634510) |
| June 4, 2026 | NCT07627555 | Polyunsaturated Fatty Acids-based Bars Effect on Metabolic Syndrome Patients | University of Lahore | Not applicable | Completed | Dyslipidemia, Metabolic Syndrome (MetS) | 60 | Pakistan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07627555) |
| June 3, 2026 | NCT07622433 | A Phase I, Cross-over Study Comparing the Relative Bioavailability of Laroprovstat Plus Ezetimibe Fixed Combination Drug Products Versus... | AstraZeneca | Phase 1 | Completed | Healthy Participants | 18 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07622433) |
| June 1, 2026 | NCT07616570 | Serum Adipokines and Metabolic Parameters With Hormone Replacement in Newly Diagnosed Hypothyroidism | Başakşehir Çam & Sakura City Hospital | Observational | Completed | Hypothyroidism, Primary Hypothyroidism, Metabolic Syndrome | 88 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07616570) |
| May 29, 2026 | NCT07614659 | Uppsala Self-Screening of Cardiovascular Health | Johan Sundström | Not applicable | Recruiting | Cardiovascular Diseases, Hypertension, Dyslipidemias, Diabetes Mellitus, Atrial Fibrillation, Chronic Kidney Disease | 45,000 | Sweden | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07614659) |
| May 27, 2026 | NCT07610304 | Effect of Alpha Tocopherol and Psyllium on Lipid Levels in Dyslipidaemia Patients | NUR International University | Phase 2 | Completed | Dyslipidaemia | 60 | Pakistan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07610304) |
| May 15, 2026 | NCT07590167 | A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C | Addpharma Inc. | Phase 1 | Not yet recruiting | Dyslipidemia, Hypertension | 60 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07590167) |
| May 14, 2026 | NCT07588256 | New Taipei City 888 Digital Medical AI Platform for Prevention and Care of the Three Highs and Cardio-Renal-Vascular Diseases | New Taipei City Medical Association | Not applicable | Recruiting | Microalbuminuria, Microalbuminuria /Creatinine Ratios ACR, Cardiovascular Disease Risk Factor, Cardiovascular Disease... | 4,162 | Taiwan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07588256) |
| May 12, 2026 | NCT07581028 | Bioequivalence Study of AJU-C715 and C715R in Healthy Adult Volunteers | AJU Pharm Co., Ltd. | Phase 1 | Completed | Hypercholerolemia, Dyslipidemia | 61 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07581028) |
| April 30, 2026 | NCT07559110 | Supplementation With Salicornia Extract Rich in Polyphenols (B-Salicornia) to Improve Vascular Health in Patients With Dyslipidemia Who Are... | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Not applicable | Not yet recruiting | Dyslipidemia | 250 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07559110) |
| April 27, 2026 | NCT07552571 | Goal Commitment and Proactive Health Behavior in Chronic Disease Patients | Xiong Juyang | Not applicable | Recruiting | Hypertension, Diabetes Mellitus, Dyslipidemia | 600 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07552571) |
| April 27, 2026 | NCT07551960 | Pilot Validation of the STELA Preventive Medicine Platform to Reduce Modifiable Health Risk Factors in Adults (CPM-STELA) | Nemocnice AGEL Trinec-Podlesi a.s. | Not applicable | Enrolling by invitation | Cardiovascular Risk Factors, Insulin Resistance, Obesity, Dyslipidemias, Metabolic Syndrome | 100 | Czechia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07551960) |
| April 24, 2026 | NCT07551505 | Safety, PK, and PD of BSA204 in Chinese Adults With Borderline Elevated Lipoprotein(a) | Bisirna Therapeutics (Suzhou) Co., Ltd. | Phase 1 | Active not recruiting | Dyslipidemias | 40 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07551505) |
| April 22, 2026 | NCT07545005 | Impact of a Produce Prescription Program and Nutrition Education Intervention on Cardiovascular Health in Youth | Boston Children's Hospital | Not applicable | Not yet recruiting | Dyslipidemia, Hypertension, Obesity & Overweight | 150 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07545005) |
| April 22, 2026 | NCT07543718 | Group Medical Visits for Patients With Dyslipidemia | Université de Sherbrooke | Not applicable | Recruiting | Dyslipidemias | 288 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07543718) |
| April 13, 2026 | NCT07524101 | Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD | Yonsei University | Not applicable | Recruiting | Renal Insufficiency, Atherosclerosis, Dyslipidemia, Hypercholesterolemia, Cardiovascular Diseases | 1,952 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07524101) |
| April 13, 2026 | NCT07523971 | Efficacy and Safety of Pitavastatin/Ezetimibe in Dyslipidemia Patients With Metabolic Syndrome: An Observational Study | JW Pharmaceutical | Observational | Recruiting | Dyslipidemias | 10,000 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523971) |
| April 7, 2026 | NCT07515573 | Effect of Compound (Cardiol Forte) on Lipid And Glycemic Parameters in Low Cardiovascular Risk Individuals | U.G.A. Nutraceuticals | Not applicable | Not yet recruiting | Dyslipidemia | 50 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07515573) |
| April 7, 2026 | NCT07515560 | Efficacy and Safety of Baroezet Tablet in Korean Patients With Dyslipidemia: A Prospective Observational Study | Daewoong Pharmaceutical Co. LTD. | Observational | Not yet recruiting | Dyslipidemia | 12,000 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07515560) |
| April 7, 2026 | NCT07513571 | A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults | AstraZeneca | Phase 1 | Completed | Healthy Participants | 31 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07513571) |
| March 31, 2026 | NCT07502703 | Validation of Remote Photoplethysmography (rPPG)-Derived Cardiovascular Parameters Against Standard Clinical Measurements and Risk Scores... | Tarumanagara University | Observational | Not yet recruiting | Dyslipidemia, Angina (Stable), Coronary Artery Disease (CAD), Heart Disease, Hypertension, Diabetes (DM) | 300 | Indonesia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07502703) |
| March 27, 2026 | NCT07497776 | Atorvastatin Therapy in the Treatment of Dyslipidemia in Children With Steroid Sensitive Nephrotic Syndrome | National Institute of Kidney Disease and Urology (NIKDU) | Phase 4 | Completed | Dyslipidaemia | 100 | Bangladesh | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07497776) |
| March 25, 2026 | NCT07492264 | Evaluation of Food Supplementation in Subjects With Suboptimal Levels of LDL Cholesterol | Cooper Consumer Health | Not applicable | Completed | Dyslipidaemia | 90 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07492264) |
| March 24, 2026 | NCT07491172 | A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias | CRISPR Therapeutics AG | Phase 1 | Recruiting | Cardiovascular, Metabolic Disease, Dyslipidemias, Lipid Disorder, Hypertriglyceridemia, Heterozygous Familial... | 90 | Australia, New Zealand, United Kingdom, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07491172) |
| March 24, 2026 | NCT07489209 | A Dose-exploration Study of EDP167 in HoFH | Eddingpharm (Zhuhai) Co., Ltd. | Phase 2 | Recruiting | Homozygous Familial Hypercholesterolemia (HoFH) | 20 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07489209) |
| March 17, 2026 | NCT07476703 | Expanded Studies on the SCAPIS Stockholm Reexamination Cohort | Danderyd Hospital | Observational | Active not recruiting | Coronary Artery Disease, Arterial Stiffness, Blood Pressure, AORTIC VALVE DISEASES, Mitral Valve Stenosis and/or... | 1,400 | Sweden | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07476703) |
| March 17, 2026 | NCT07476248 | The Non-high-density Lipoprotein Cholesterol (Non-HDL-C) to High-density Lipoprotein Cholesterol (HDL-C) Ratio (NHHR) and Its Association... | Assiut University | Observational | Not yet recruiting | Diabetic Nephropathy, Dyslipidemia | 84 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07476248) |
| March 16, 2026 | NCT07474233 | Associations Between Dietary Patterns, LDL Aggregation, and Cardiometabolic Health | Liverpool John Moores University | Observational | Not yet recruiting | Atherosclerosis Cardiovascular Disease, Metabolic Syndrome, Dyslipidaemia, Endothelial Dysfunction | 90 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07474233) |
| March 16, 2026 | NCT07473843 | Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia | Arrowhead Pharmaceuticals | Phase 3 | Recruiting | Homozygous Familial Hypercholesterolemia | 10 | Denmark, Poland, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07473843) |
| March 12, 2026 | NCT07468500 | Real World Adherence of PCSK9 Targeted Therapy | Novartis Pharmaceuticals | Observational | Not yet recruiting | Dyslipidemia, Hypercholesterolemia | 3,600 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07468500) |
| March 10, 2026 | NCT07462871 | Comparative Effects of Carnivore and Mediterranean-style Diets on LDL Aggregation and Cardiometabolic Health | Liverpool John Moores University | Not applicable | Not yet recruiting | Atherosclerosis Cardiovascular Disease, Metabolic Syndrome, Dyslipidaemia | 30 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07462871) |
| March 3, 2026 | NCT07447362 | Clinical Management of Cardiovascular Risk Factors in Adult Patients: A Before-and-After Interventional Study | Universidad Católica San Antonio de Murcia | Not applicable | Recruiting | Cardiovascular Risk Factors, Hypertension, Dyslipidemia, Type 2 Diabetes Mellitus, Obesity, Overweight, Tobacco Use | 220 | Chile | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07447362) |
| March 3, 2026 | NCT07445542 | Efficacy and Safety of Pitavastatin/Ezetimibe After Switching From Statin Monotherapy to Pitavastatin/Ezetimibe in Patients With... | JW Pharmaceutical | Observational | Completed | Hypercholesterolemia | 6,927 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07445542) |
| February 20, 2026 | NCT07423884 | Effect of a Low-Calorie MCT-Rich Traditional Minangkabau Diet on Obese Individuals | Andalas University | Not applicable | Not yet recruiting | Metabolically Unhealty Obese, Dyslipidemia, Diabetes (DM), Resistance, Insulin, Obesity | 40 | Indonesia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07423884) |
| February 20, 2026 | NCT07423598 | A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics With AZD0780 Following Repeated Dose Administration in... | AstraZeneca | Phase 1 | Completed | Healthy Participants | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07423598) |
| February 17, 2026 | NCT07412457 | Guideline Adherence in Dyslipidemia With Clinical Decision Support | I.M. Sechenov First Moscow State Medical University | Observational | Not yet recruiting | Dyslipidemia, Coronary Artery Disease, Atherosclerosis of Major Arteries, Cardiovascular Risk, Subclinical... | 500 | Russia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07412457) |
| February 17, 2026 | NCT07412080 | EDP167 in Healthy Volunteers and Subjects With Mild Dyslipidemia | Eddingpharm (Zhuhai) Co., Ltd. | Phase 1 | Completed | Healthy Adult Male and Female Volunteers, Mild Dyslipidemia | 40 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07412080) |
| February 10, 2026 | NCT07401017 | The Effects of Rosuvastatin on Running Training Adaptation and Safety | Taipei Medical University WanFang Hospital | Not applicable | Not yet recruiting | Dyslipidemia, Long-Distance Running, Endurance Training, Statin-Associated Muscle Symptoms | 40 | Taiwan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07401017) |
| February 4, 2026 | NCT07387393 | To Test the Effectiveness and Implementation Approach of a 3-month PILI Pasifika Program Lifestyle Program With Components of Social... | University of Hawaii | Not applicable | Enrolling by invitation | Cardiometabolic Conditions, Hypertension (HTN), Dyslipidemia, Pre-diabetes, Type 2 Diabetes Mellitus (T2DM), Overweight... | 400 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07387393) |
| January 28, 2026 | NCT07373392 | Effects of LP-LDL® on Lipid Metabolism, Glycemic Control, Inflammatory Markers, and Cognitive Function in Individuals With Prediabetes and... | Aalborg University | Not applicable | Not yet recruiting | Diabete Type 1, Diabete Type 2, Prediabetes | 210 | Denmark | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07373392) |
| January 22, 2026 | NCT07359105 | Moderate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study) | Sin Gon Kim | Not applicable | Recruiting | Dyslipidemia Associated With Type II Diabetes Mellitus | 2,186 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07359105) |
| January 20, 2026 | NCT07350486 | LLM-CoManage: Large Language Model-Enabled Co-Management of Hypertension, Diabetes, and Dyslipidemia | First Hospital of China Medical University | Not applicable | Active not recruiting | Hypertension, Diabetes, Dyslipidemia | 6,800 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07350486) |
| January 14, 2026 | NCT07340580 | Implementation Facilitation of Exercise is Medicine Greenville | University of South Carolina | Not applicable | Not yet recruiting | Physical Inactivity, Dyslipidemia, Obesity and Overweight, Hypertension, Diabetes, Health Care Delivery, Patients... | 35 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07340580) |
| January 5, 2026 | NCT07316608 | A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy... | AstraZeneca | Phase 1 | Completed | Healthy Participants | 44 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07316608) |
| January 2, 2026 | NCT07314775 | Yangxin Dawayimixike Honey Paste for Carotid Atherosclerotic Plaque With Dyslipidemia: A Randomized Controlled Clinical Study | Xinjiang Uygur Pharmaceutical Co., Ltd. | Phase 4 | Not yet recruiting | Dyslipidemia, Carotid Atherosclerotic Plaques | 422 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07314775) |
| December 30, 2025 | NCT07310849 | Digital Care for Holistic Health in Older Adults With Diabetes and Multimorbidity | Chang Gung University of Science and Technology | Not applicable | Recruiting | Type2Diabetes, Hypertension, Dyslipidemia, CKD, Cardio Vascular Disease, Gout Arthritis | 169 | Taiwan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07310849) |
| December 29, 2025 | NCT07308314 | Taining Golden Lake Comprehensive Chronic Disease Management Initiative | First Affiliated Hospital of Fujian Medical University | Observational | Recruiting | Chronic Disease, Chronic Disease Management, Hypertension, Diabetes Mellitus, Dyslipidemias, Frailty, Sarcopenia | 20,000 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07308314) |
| December 23, 2025 | NCT07298564 | Effect of Magnesium and Levocarnitine on Metabolic and Clinical Outcomes in Women With Polycystic Ovarian Syndrome (PCOS) | Behnood Abbasi | Not applicable | Recruiting | Polycystic Ovary Syndrome (PCOS) | 84 | Iran | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07298564) |
| December 8, 2025 | NCT07269795 | Advanced Strategy of Food Supplements for the Optimization of Satiety and Lipid Metabolism in Maturity (SACIANS) | University of Alicante | Not applicable | Completed | Dyslipidemia, Lipid Metabolism, Satiety Response, Overweight and/or Obesity | 80 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07269795) |
| December 8, 2025 | NCT07268781 | Impact of Golden Rice-Piper Crocatum Cookies on Lipid Control in Diabetes Mellitus Patients | Hasanuddin University | Not applicable | Completed | Diabetes Mellitus (DM), Dyslipidemia, Lipid Profile, Functional Food, Nutritional Intervention, Cardiovascular Risk... | 102 | Indonesia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07268781) |
| December 1, 2025 | NCT07255820 | Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol | Bahria University | Phase 4 | Completed | Type 2 Diabetes Mellitus, Hypercholesterolemia / Elevated LDL Cholesterol | 126 | Pakistan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07255820) |
| November 24, 2025 | NCT07246408 | Intermittent Cottonseed Oil Consumption | University of Georgia | Not applicable | Recruiting | Dyslipidemia, Overweight and Obesity, Nutrition, Healthy | 75 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07246408) |
| November 20, 2025 | NCT07238556 | A Novel Digital Tool Clinicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors | University of Connecticut | Not applicable | Recruiting | Hypertension, Dyslipidemia, Diabetes Mellitus, Obesity, Cardiovascular Disease | 72 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07238556) |
| November 19, 2025 | NCT07235046 | A Study of DII235 in Adults With Elevated Lipoprotein(a) | Novartis Pharmaceuticals | Phase 2 | Active not recruiting | Lipoprotein Disorder | 234 | China, Germany, Japan, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07235046) |
| October 27, 2025 | NCT07221279 | Prescription of Step Counts for Targeted Changes in Body Composition and Cardiometabolic Risk in Overweight/Obese Adults | Kennesaw State University | Not applicable | Recruiting | Dyslipidemia, Insulin Resistance Syndrome, Hypertension, Inflammation Chronic, Obesity & Overweight | 200 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07221279) |
| October 21, 2025 | NCT07218900 | A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels... | AstraZeneca | Phase 2 | Completed | Dyslipidaemia | 76 | Russia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07218900) |
| October 14, 2025 | NCT07216131 | A Study to Investigate the Effect of AZD0780 on Metformin Pharmacokinetics in Healthy Adult Volunteers Aged 18 to 55 Years | AstraZeneca | Phase 1 | Completed | Healthy Participants | 14 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07216131) |
| October 6, 2025 | NCT07208331 | Evaluation of an Integrated, Digital, Nurse-led, Remote Monitoring Care Pathway for Cardiovascular Risk Management | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Observational | Recruiting | Atherosclerotic Cardiovascular Disease (ASCVD), Hypertension, Dyslipidemia | 750 | Netherlands | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07208331) |
| October 3, 2025 | NCT07206875 | Observational Study for the Characterisation of Patients Affected by Any Type of Diabetes and Endocrine Disorders | IRCCS San Raffaele | Observational | Recruiting | Diabetes, Metabolic Disorders, Arterial Hypertension, Dyslipidemia, Liver Disease (Alcoholic or Not) | 10,000 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07206875) |
| September 26, 2025 | NCT07194577 | Effect of Moringa Oleifera Dehydrated Leaf Powder on the Components of Metabolic Syndrome in Mexican Adults. | Universidad de Colima | Not applicable | Completed | Nutritional and Metabolic Diseases, Metabolic Syndrome | 36 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07194577) |
| September 17, 2025 | NCT07178444 | Evaluation of the Effectiveness of an Interdisciplinary Intervention After Acute Coronary Syndrome on Low-Density Lipoprotein Cholesterol... | Assistance Publique - Hôpitaux de Paris | Not applicable | Not yet recruiting | Acute Coronary Syndromes (ACS), Acute Coronary Syndromes | 230 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07178444) |
| September 16, 2025 | NCT07175766 | Dachundou No Sugar Added Soymilk for Lipid Modulation | National Taiwan Sport University | Not applicable | Completed | Dyslipidemias, Hypercholesterolemia, Cardiovascular Diseases | 25 | Taiwan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07175766) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| AstraZeneca | 9 | June 3, 2026 |
| Eddingpharm (Zhuhai) Co., Ltd. | 3 | September 2, 2026 |
| Korea United Pharm. Inc. | 3 | July 8, 2026 |
| AJU Pharm Co., Ltd. | 3 | June 18, 2026 |
| JW Pharmaceutical | 3 | April 13, 2026 |
| Novartis Pharmaceuticals | 3 | March 12, 2026 |
| Mahidol University | 2 | October 19, 2026 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2 | August 20, 2026 |
| University of Georgia | 2 | July 10, 2026 |
| Taipei Medical University | 2 | July 9, 2026 |
| Daewoong Pharmaceutical Co. LTD. | 2 | April 7, 2026 |
| Liverpool John Moores University | 2 | March 16, 2026 |
| University of Toronto | 2 | April 9, 2025 |
| HK inno.N Corporation | 1 | November 9, 2026 |
| Rovere Querini Patrizia | 1 | November 5, 2026 |
| China National Center for Cardiovascular Diseases | 1 | November 4, 2026 |
| University of Applied Sciences in Nowy Targ | 1 | November 4, 2026 |
| Universiti Teknologi Mara | 1 | November 4, 2026 |
| Rehman Medical Institute - RMI | 1 | November 2, 2026 |
| Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | 1 | November 2, 2026 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 73 | November 4, 2026 |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 33 | November 9, 2026 |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 24 | August 20, 2026 |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 8 | November 4, 2026 |
| [Phase 4](https://specstream.ai/data/clinical-trials/phase/phase-4) | 8 | November 2, 2026 |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 4 | March 16, 2026 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 2 | October 26, 2026 |
| [Phase 2/3](https://specstream.ai/data/clinical-trials/phase/phase-2-3) | 1 | February 19, 2025 |

## By country

| Country | New trials | Latest |
| --- | --- | --- |
| [South Korea](https://specstream.ai/data/clinical-trials/country/south-korea) | 21 | November 9, 2026 |
| [United States](https://specstream.ai/data/clinical-trials/country/united-states) | 19 | July 10, 2026 |
| [China](https://specstream.ai/data/clinical-trials/country/china) | 17 | October 21, 2026 |
| [Taiwan](https://specstream.ai/data/clinical-trials/country/taiwan) | 9 | September 17, 2026 |
| [Italy](https://specstream.ai/data/clinical-trials/country/italy) | 8 | November 5, 2026 |
| [Turkey (Türkiye)](https://specstream.ai/data/clinical-trials/country/turkey-t-rkiye) | 5 | October 13, 2026 |
| [Canada](https://specstream.ai/data/clinical-trials/country/canada) | 5 | July 6, 2026 |
| [United Kingdom](https://specstream.ai/data/clinical-trials/country/united-kingdom) | 5 | March 24, 2026 |
| [Malaysia](https://specstream.ai/data/clinical-trials/country/malaysia) | 4 | November 4, 2026 |
| [Pakistan](https://specstream.ai/data/clinical-trials/country/pakistan) | 4 | November 2, 2026 |
| [Mexico](https://specstream.ai/data/clinical-trials/country/mexico) | 4 | September 18, 2026 |
| [Russia](https://specstream.ai/data/clinical-trials/country/russia) | 4 | February 17, 2026 |
| [Australia](https://specstream.ai/data/clinical-trials/country/australia) | 3 | October 26, 2026 |
| [Denmark](https://specstream.ai/data/clinical-trials/country/denmark) | 3 | August 24, 2026 |
| [Sweden](https://specstream.ai/data/clinical-trials/country/sweden) | 3 | May 29, 2026 |
| [Indonesia](https://specstream.ai/data/clinical-trials/country/indonesia) | 3 | March 31, 2026 |
| [Netherlands](https://specstream.ai/data/clinical-trials/country/netherlands) | 3 | October 6, 2025 |
| [Poland](https://specstream.ai/data/clinical-trials/country/poland) | 2 | November 4, 2026 |
| [Thailand](https://specstream.ai/data/clinical-trials/country/thailand) | 2 | October 19, 2026 |
| [Brazil](https://specstream.ai/data/clinical-trials/country/brazil) | 2 | July 20, 2026 |
| [Jordan](https://specstream.ai/data/clinical-trials/country/jordan) | 2 | June 16, 2026 |
| [Spain](https://specstream.ai/data/clinical-trials/country/spain) | 2 | April 30, 2026 |
| [Japan](https://specstream.ai/data/clinical-trials/country/japan) | 2 | November 19, 2025 |
| [France](https://specstream.ai/data/clinical-trials/country/france) | 2 | September 17, 2025 |
| [Portugal](https://specstream.ai/data/clinical-trials/country/portugal) | 2 | March 17, 2025 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).